Mesirow Financial Investment Management Inc. Sells 98,974 Shares of Pfizer Inc. $PFE

Mesirow Financial Investment Management Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 35.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 181,639 shares of the biopharmaceutical company’s stock after selling 98,974 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Pfizer were worth $4,523,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. State Street Corp increased its stake in shares of Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after buying an additional 2,786,098 shares during the period. Northern Trust Corp increased its stake in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after acquiring an additional 897,786 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after acquiring an additional 3,296,415 shares during the period. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won European Commission approval to expand HYMPAVZI (marstacimab) for hemophilia A or B patients with inhibitors, a new label expansion that could support future revenue growth. Pfizer wins Hympavzi label expansion Europe
• Positive Sentiment: Pfizer also highlighted ongoing pipeline progress, including a new Japan RSV vaccine phase 3 trial and a prazosin site-transfer study, signaling continued development activity and supply-chain execution. Pfizer’s New Japan RSV Vaccine Trial Pfizer’s Prazosin Site-Transfer Trial
• Positive Sentiment: Some commentary argues Pfizer has effectively “locked in” several years of growth by clearing a major patent hurdle and redirecting cash toward other profit centers, which supports the bull case. Pfizer Just Locked In Its Next 5 Years of Growth

Pfizer Stock Performance

PFE stock opened at $25.74 on Friday. Pfizer Inc. has a one year low of $22.09 and a one year high of $28.75. The firm has a market cap of $146.70 billion, a price-to-earnings ratio of 19.65 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a 50-day simple moving average of $27.01 and a two-hundred day simple moving average of $26.19.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is presently 131.30%.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent research reports. Citigroup increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Royal Bank Of Canada reissued an “underperform” rating and issued a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.84.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.